Comparing the current results to its competitors, Avid Bioservices Inc reported Revenue increase in the 2 quarter 2024 by 32.16 % year on year. The sales growth was above Avid Bioservices Inc 's competitors' average revenue growth of 12.27 %, achieved in the same quarter.
Avid Bioservices Inc 's Comment on Competition and Industry Peers
The company operates in the contract development and manufacturing organization (CDMO) market, competing with full-service contract manufacturers and large pharmaceutical companies that insource manufacturing. Some pharmaceutical companies are divesting manufacturing capacity, which competitors may acquire. Larger global competitors have significantly greater financial, marketing, technical, and other resources. Emerging competition may create downward pricing pressure, potentially affecting the company's financial condition.
May 21, 2024
Investing in the stock market can be highly rewarding, but it also carries a certain degree of risk. As shareholders, we place our trust in companies and their management to make sound decisions that will benefit us. However, there are instances when this trust is betrayed, and investors suffer significant losses as a result. One such case has caught the attention of the renowned Pomerantz Law Firm, which is currently investigating claims against Avid Bioservices, Inc. (CDMO), a prominent player in the biotechnology industry.The probe launched by Pomerantz LLP follows allegations of potential investor misconduct involving Avid Bioservices, Inc. These claims have prompted the law firm to urge all affected inv...
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Exicure Inc operates on a business model focused on developing and commercializing transformative gene therapy drugs utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to leverage its platform to create therapeutic solutions for various diseases by delivering genetic medicines directly to cells. By collaborating with partners or independently, Exicure Inc aims to advance its pipeline and ultimately bring innovative treatments to the market.
Adial Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing medications for the treatment of alcohol use disorder. Their business model revolves around conducting clinical trials, obtaining regulatory approvals, and marketing their products to healthcare professionals and potential patients.
Catalent Incs business model centers around offering comprehensive development and delivery solutions to pharmaceutical, biotechnology, and consumer health companies. By providing a diverse array of services such as drug development, manufacturing, packaging, and supply chain management, they aim to expedite the market entry of innovative and life-saving products for their clients.
Sources:
Avid Bioservices Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Avid Bioservices Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
